ALTEOGEN Inc.
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 196170.KQ | 068270.KS | 0MGB.IL | ALXO | 9926.HK | APVO | |
|---|---|---|---|---|---|---|
| Market cap | 14.70T | 49.02T | 296.46B | 188.06M | 80.92B | 2.90M |
| P/E (TTM) | — | — | 52.3 | — | — | 0.0 |
| Forward P/E | — | — | — | -2.5 | 60.4 | -0.1 |
| Price/book | — | — | 8.4 | 1.4 | 8.1 | 0.3 |
| Dividend yield | 0.14% | 0.36% | — | — | — | — |
| 1-year change | −49.87% | +20.07% | +93.74% | +15.25% | −27.63% | −94.82% |
| Today | +3.68% | +7.50% | +2.19% | +5.43% | +6.48% | +0.74% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All 196170.KQ news ›Alteogen's Quarterly Revenue Tops 100 Billion Won for First Time
Alteogen's third-quarter revenue rose 144.4% to 119.8 billion won, its first quarter above 100 billion won, on Keytruda SC sales and ALT-B4 licensing. Alteogen (196170.KQ) posted quarterly revenue above 100 billion won for the first time…
Alteogen confronts stock slide as leaders bet on mergers and DDS-fueled growth
Shareholders press Jeon Tae-yeon and Park Soon-jae on near-term growth as mergers advance and Keytruda SC faces European patent hurdles They said they would reach 4 trillion won in sales by 2035 through a merger of subsidiaries and…
Alteogen Patent Setback in Netherlands May Be Reversed, Analyst Says
Seoul Economic Daily A Dutch court injunction barring the manufacture, sale and import of a subcutaneous version of Keytruda in eight European countries, based on a Halozyme patent, has renewed concerns over patent disputes surroun
Alteogen Joins Growing List of Biotechs Backed by National Growth Fund
Five Drugmakers Secure Funding This Year Support Spans Late-Stage Trials to Plant Expansion Attention Turns to Medical Devices and AI Alteogen plans to issue a combined 200 billion won in classified shares to SkyAlt, a vehicle jointly…
Could Alteogen Patent Dispute Spread Beyond Keytruda? Dutch Ruling Offers Clues
Published 11 Oct.2026 18:01(KST) Merck (MSD)'s immunotherapy drug Keytruda in a subcutaneous (SC) formulation. Its U.S. brand name is Keytruda Qlex. MSD Alteogen has licensing agreements for ALT-B4 with 10 global pharmac
Alteogen merges subsidiary to centralize R&D, approvals, and sales in Korea
Alteogen said on the 6th that its board met and decided to absorb and merge Alteogen Biologics through a small-scale merger. The merger agreement is set to be signed on the 7th. The merger date is Dec. 29. Alteogen holds 62.9% equity in…
Alteogen raises 200 billion won to build plant, import tech for growth beyond ALT-B4
Fresh funding targets Daejeon plant build-out and external biologics to diversify beyond the ALT-B4 platform Alteogen(196170) will attract 200 billion won in investment and move to build new production facilities and introduce external…
South Korea's Alteogen to Absorb Subsidiary, Moving Beyond Tech Licensing to Direct Sales
South Korea's Alteogen (196170) will absorb its subsidiary Alteogen Biologics through a merger. The decision marks a shift away from a business structure centered on technology licensing of its subcutaneous injection formulation platform…
Alteogen Raises 200 Billion Won to Build Plant, Diversify Platforms
■AI PRISM [Startup News] Alteogen Issues 100 Billion Won Each in CPS and RCPS Elice Group Prices IPO at Top of Range at 90,500 Won Tving, Toss Payments, Gangnam Unni Apologize at Audit ■ Policy Fund Investment: Alteogen (196170) will issue…
Alteogen to Absorb Subsidiary Alteogen Biologics
Global Trial, Regulatory and Sales Capabilities to Be Brought In-House Move Strengthens Base for Commercializing In-House Products Alteogen said on the 6th that it decided to absorb its subsidiary Alteogen Biologics through a small-scale…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- en.sedaily.com5
- biz.chosun.com3
- asiae.co.kr2
- finance.biggo.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 12 articles, not a forecast.